Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
OncoSil Medical LtdTelephone
61.2.8935.9629
Address
Level 5 7 Eden Park Drive Macquarie Park, New South Wales (NSW) 2113
Description
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$5,713.00
1 week
0%
1 month
100%
YTD
5.88%
1 year
-20.59%
All time high
0.20
EPS 3 yr Growth
92.300%
EBITDA Margin
%
Operating Cashflow
-$11m
Free Cash Flow Return
-106.70%
ROIC
-107.00%
Interest Coverage
-1,135.60
Quick Ratio
7.20
Shares on Issue (Fully Dilluted)
2092m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
25 July 24 |
Australian institution to invest $2.7 million in OSL
×
Australian institution to invest $2.7 million in OSL |
25 July 24 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
25 July 24 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
23 July 24 |
Investor Presentation
×
Investor Presentation |
15 July 24 |
Director Appointment/Resignation PH
×
Director Appointment/Resignation PH |
15 July 24 |
Peter Hall to be appointed Non-Executive Director (addendum)
×
Peter Hall to be appointed Non-Executive Director (addendum) |
12 July 24 |
Letter to Short Dated Option Holders
×
Letter to Short Dated Option Holders |
10 July 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
10 July 24 |
OSL Short Dated Options Range of Units and Top 20 Holders
×
OSL Short Dated Options Range of Units and Top 20 Holders |
03 July 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
03 July 24 |
Notification regarding unquoted securities - OSL
×
Notification regarding unquoted securities - OSL |
24 June 24 |
Notification regarding unquoted securities - OSL
×
Notification regarding unquoted securities - OSL |
21 June 24 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
11 June 24 |
5th patient is treated in PANCOSIL trial
×
5th patient is treated in PANCOSIL trial |
03 June 24 |
200th patient treated with the OncoSil device
×
200th patient treated with the OncoSil device |
23 May 24 |
OncoSil signs distribution agreement for Saudi Arabia
×
OncoSil signs distribution agreement for Saudi Arabia |
20 May 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
20 May 24 |
Notification regarding unquoted securities - OSL
×
Notification regarding unquoted securities - OSL |
20 May 24 |
Change in substantial holding
×
Change in substantial holding |
15 May 24 |
Results of Meeting
×
Results of Meeting |
15 May 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
15 May 24 |
Notification regarding unquoted securities - OSL
×
Notification regarding unquoted securities - OSL |
10 May 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
10 May 24 |
Notification regarding unquoted securities - OSL
×
Notification regarding unquoted securities - OSL |
08 May 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.